Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: This case was reported by a other health professional via call center representative and described the occurrence of facial swelling in a 16-year-old female patient who received BEXSERO (batch number L045711, expiry date 8th May 2017). Concomitant products included GARDASIL. On 27th February 2016, the patient received 1st dose of BEXSERO. In February 2016, 1 day after receiving BEXSERO, the patient experienced facial swelling. On 5th March 2016, the outcome of the facial swelling was recovered/resolved. It was unknown if the reporter considered the facial swelling to be related to BEXSERO. Additional details provided were as follows: The patient had received GARDASIL previously with no adverse reactions. The patient experienced face swelling which lasted for 1 week and which was described as severe, uncomfortable, and embarrassing. There were no other associated symptoms.
Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166